TVTX insider buying and SEC filings, explained
Travere Therapeutics, Inc. · CIK 1438533
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- CA
- Fiscal year end
- Dec 31
- Former names
- Retrophin, Inc.; Desert Gateway, Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.5M
Planned sales (10b5-1)
$112.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 243,735 shares at about $53.82 ($13.1M), marked as a 10b5-1 plan trade. Holdings down 36% to 432,886 shares. | SEC filing Filed Oct 19, 2026, 4:05 PM ET |
| Sep 15, 2026 | Planned (10b5-1) | Christopher R. Cline (CFO) sold 50,508 shares at about $62.34 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 37% to 87,508 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Jula Inrig (EVP, Head of R&D & CMO) sold 44,674 shares at about $62.34 ($2.8M), marked as a 10b5-1 plan trade. Holdings down 31% to 100,491 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Sandra Calvin (SVP, Chief Accounting Officer) sold 5,375 shares at about $62.33 ($335K), marked as a 10b5-1 plan trade. Holdings down 11% to 42,353 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 15–17, 2026 | Planned (10b5-1) | Peter Heerma (EVP, Chief Commercial Officer) sold 283,189 shares between Sep 15 and Sep 17 at about $63.06 ($17.9M), marked as a 10b5-1 plan trade. Holdings down 71% to 117,066 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 15–17, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 400,000 shares between Sep 15 and Sep 17 at about $63.48 ($25.4M), marked as a 10b5-1 plan trade. Holdings down 48% to 432,886 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 15–16, 2026 | Planned (10b5-1) | William E. Rote (Chief Research Officer) sold 209,048 shares between Sep 15 and Sep 16 at about $62.83 ($13.1M), marked as a 10b5-1 plan trade. Holdings down 68% to 98,197 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 37,500 shares at about $62.34 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 26% to 105,389 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 10, 2026 | Planned (10b5-1) | Jeffrey A Meckler (Director) sold 20,000 shares at about $67.30 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 18% to 91,500 shares. | SEC filing Filed Sep 11, 2026 |
| Sep 2, 2026 | Sale | Christopher R. Cline (CFO) sold 642 shares at $66.37 ($43K). Holdings down 1% to 118,016 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 3, 2026 |
| Aug 17–18, 2026 | Planned (10b5-1) | Gary A. Lyons (Director) sold 10,000 shares between Aug 17 and Aug 18 at about $63.29 ($633K), marked as a 10b5-1 plan trade. Holdings down 14% to 61,500 shares. | SEC filing Filed Aug 19, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Roy D. Baynes (Director) sold 4,500 shares at $50.00 ($225K), marked as a 10b5-1 plan trade. Holdings down 10% to 41,500 shares. | SEC filing Filed Jun 16, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Timothy Coughlin (Director) sold 10,000 shares at about $50.07 ($501K), marked as a 10b5-1 plan trade. Holdings down 15% to 56,250 shares. | SEC filing Filed Jun 16, 2026 |
| May 15, 2026 | Planned (10b5-1) | Timothy Coughlin (Director) sold 3,250 shares at $43.49 ($141K), marked as a 10b5-1 plan trade. Holdings down 6% to 52,250 shares. | SEC filing Filed May 19, 2026 |
| May 5, 2026 | Planned (10b5-1) | Roy D. Baynes (Director) sold 4,500 shares at $46.65 ($210K), marked as a 10b5-1 plan trade. Holdings down 11% to 37,500 shares. | SEC filing Filed May 6, 2026 |
| May 5–6, 2026 | Planned (10b5-1) | Christopher R. Cline (CFO) sold 2,491 shares between May 5 and May 6 at about $46.31 ($115K), marked as a 10b5-1 plan trade. Holdings down 2% to 118,658 shares. | SEC filing Filed May 6, 2026 |
| May 4–6, 2026 | Planned (10b5-1) | Jula Inrig (Chief Medical Officer) sold 22,485 shares between May 4 and May 6 at about $45.15 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 17% to 113,238 shares. | SEC filing Filed May 6, 2026 |
| May 5, 2026 | Sale | Peter Heerma (Chief Commercial Officer) sold 2,174 shares at $46.65 ($101K). Holdings down 2% to 140,684 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 6, 2026 |
| May 6, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 22,500 shares at $43.95 ($989K), marked as a 10b5-1 plan trade. Holdings down 5% to 432,886 shares. | SEC filing Filed May 6, 2026 |
| May 6, 2026 | Planned (10b5-1) | William E. Rote (Chief Research Officer) sold 2,763 shares at $43.95 ($121K), marked as a 10b5-1 plan trade. Holdings down 2% to 115,474 shares. | SEC filing Filed May 6, 2026 |
| May 4, 2026 | Planned (10b5-1) | Jeffrey A Meckler (Director) sold 8,000 shares at $45.00 ($360K), marked as a 10b5-1 plan trade. Holdings down 8% to 87,500 shares. | SEC filing Filed May 6, 2026 |
| May 4–6, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 24,250 shares between May 4 and May 6 at about $45.06 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 19% to 105,211 shares. | SEC filing Filed May 6, 2026 |
| May 1, 2026 | Planned (10b5-1) | Roy D. Baynes (Director) sold 9,750 shares at $44.22 ($431K), marked as a 10b5-1 plan trade. Holdings down 21% to 37,500 shares. | SEC filing Filed May 4, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | William E. Rote (Chief Research Officer) sold 9,100 shares at $39.09 ($356K), marked as a 10b5-1 plan trade. Holdings down 7% to 113,987 shares. | SEC filing Filed Apr 23, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Sandra Calvin (SVP, Chief Accounting Officer) sold 21,977 shares at $41.07 ($903K), marked as a 10b5-1 plan trade. Holdings down 34% to 42,353 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Roy D. Baynes (Director) sold 32,750 shares at about $41.29 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 47% to 37,500 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Gary A. Lyons (Director) sold 8,000 shares at $41.07 ($329K), marked as a 10b5-1 plan trade. Holdings down 12% to 57,500 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 13–15, 2026 | Planned (10b5-1) | Christopher R. Cline (CFO) sold 8,327 shares between Apr 13 and Apr 15 at about $41.91 ($349K), marked as a 10b5-1 plan trade. Holdings down 7% to 116,899 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 14–15, 2026 | Planned (10b5-1) | Jula Inrig (Chief Medical Officer) sold 8,233 shares between Apr 14 and Apr 15 at about $42.01 ($346K), marked as a 10b5-1 plan trade. Holdings down 7% to 111,473 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 14, 2026 | Sale | Peter Heerma (Chief Commercial Officer) sold 7,215 shares at $41.93 ($303K). Holdings down 5% to 138,608 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 15, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 64,000 shares at about $41.09 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 13% to 432,886 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 14–15, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 51,500 shares between Apr 14 and Apr 15 at about $41.29 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 33% to 105,211 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Roy D. Baynes (Director) sold 10,000 shares at $33.00 ($330K), marked as a 10b5-1 plan trade. Holdings down 21% to 37,500 shares. | SEC filing Filed Apr 7, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 60,000 shares at about $30.93 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 12% to 432,886 shares. | SEC filing Filed Apr 2, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 10,000 shares at $30.00 ($300K), marked as a 10b5-1 plan trade. Holdings down 9% to 105,211 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 10,000 shares at about $28.09 ($281K), marked as a 10b5-1 plan trade. Holdings down 9% to 105,211 shares. | SEC filing Filed Mar 18, 2026 |
| Feb 20, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 60,000 shares at about $30.10 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 12% to 432,886 shares. | SEC filing Filed Feb 24, 2026 |
| Feb 17, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 10,000 shares at about $27.83 ($278K), marked as a 10b5-1 plan trade. Holdings down 9% to 105,211 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Christopher R. Cline (CFO) sold 1,745 shares at about $32.19 ($56K), marked as a 10b5-1 plan trade. Holdings down 2% to 111,226 shares. | SEC filing Filed Feb 5, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Jula Inrig (Chief Medical Officer) sold 1,779 shares at about $32.21 ($57K), marked as a 10b5-1 plan trade. Holdings down 2% to 105,706 shares. | SEC filing Filed Feb 5, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 2,994 shares at about $32.18 ($96K), marked as a 10b5-1 plan trade. Holdings down 3% to 105,211 shares. | SEC filing Filed Feb 5, 2026 |
| Feb 3, 2026 | Sale | Christopher R. Cline (CFO) sold 7,242 shares at $32.12 ($233K). Holdings down 6% to 112,971 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Feb 3, 2026 | Sale | Jula Inrig (Chief Medical Officer) sold 6,956 shares at $32.12 ($223K). Holdings down 6% to 107,485 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Feb 3, 2026 | Sale | Sandra Calvin (SVP, Chief Accounting Officer) sold 4,333 shares at $32.12 ($139K). Holdings down 8% to 49,080 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Feb 3, 2026 | Sale | Peter Heerma (Chief Commercial Officer) sold 7,310 shares at $32.12 ($235K). Holdings down 5% to 131,823 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Feb 3, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 100,087 shares at about $32.28 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 19% to 432,886 shares. | SEC filing Filed Feb 3, 2026 |
| Feb 3, 2026 | Planned (10b5-1) | William E. Rote (Chief Research Officer) sold 12,446 shares at $32.87 ($409K), marked as a 10b5-1 plan trade. Holdings down 10% to 109,087 shares. | SEC filing Filed Feb 3, 2026 |
| Feb 3, 2026 | Sale | Elizabeth E. Reed (Chief Legal Officer and GC) sold 7,175 shares at $32.12 ($230K). Holdings down 6% to 108,205 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Jan 23–27, 2026 | Planned (10b5-1) | Eric M Dube (CEO and Director) sold 60,000 shares between Jan 23 and Jan 27 at about $30.09 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 13% to 419,173 shares. | SEC filing Filed Jan 27, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Elizabeth E. Reed (Chief Legal Officer and GC) sold 10,000 shares at about $27.34 ($273K), marked as a 10b5-1 plan trade. Holdings down 10% to 90,270 shares. | SEC filing Filed Jan 21, 2026 |
| Jan 5–6, 2026 | Planned (10b5-1) | Jula Inrig (Chief Medical Officer) sold 2,476 shares between Jan 5 and Jan 6 at about $39.74 ($98K), marked as a 10b5-1 plan trade. Holdings down 3% to 86,311 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 24, 2025 | Planned (10b5-1) | Jula Inrig (Chief Medical Officer) sold 15,000 shares at about $42.00 ($630K), marked as a 10b5-1 plan trade. Holdings down 14% to 88,787 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 24, 2025 | Planned (10b5-1) | Sandra Calvin (SVP, Chief Accounting Officer) sold 7,402 shares at $40.00 ($296K), marked as a 10b5-1 plan trade. Holdings down 16% to 38,233 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 24, 2025 | Planned (10b5-1) | Peter Heerma (Chief Commercial Officer) sold 4,980 shares at $40.00 ($199K), marked as a 10b5-1 plan trade. Holdings down 4% to 113,013 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 24, 2025 | Planned (10b5-1) | William E. Rote (Chief Research Officer) sold 60,000 shares at about $40.10 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 37% to 101,443 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 15, 2025 | Planned (10b5-1) | Sandra Calvin (SVP, Chief Accounting Officer) sold 2,910 shares at $36.00 ($105K), marked as a 10b5-1 plan trade. Holdings down 6% to 45,635 shares. | SEC filing Filed Dec 16, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Christopher R. Cline (CFO) sold 20,000 shares at about $35.01 ($700K), marked as a 10b5-1 plan trade. Holdings down 18% to 92,083 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Sandra Calvin (SVP, Chief Accounting Officer) sold 67,115 shares at $36.00 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 58% to 48,545 shares. | SEC filing Filed Nov 6, 2025 |
| Oct 31, 2025 | Planned (10b5-1) | Peter Heerma (Chief Commercial Officer) sold 5,591 shares at $35.00 ($196K), marked as a 10b5-1 plan trade. Holdings down 4% to 119,071 shares. | SEC filing Filed Nov 4, 2025 |
| Oct 31, 2025 | Planned (10b5-1) | Timothy Coughlin (Director) sold 18,000 shares at about $35.03 ($631K), marked as a 10b5-1 plan trade. Holdings down 24% to 55,500 shares. | SEC filing Filed Nov 4, 2025 |
61 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:05 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TVTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.